Novel treatment regimen appears well tolerated, beneficial to children with relapsed brain tumors

The first in-human-study of a new immunotherapy that blocks a natural enzyme tumors commandeer for their protection was well tolerated by children with relapsed brain tumors and enabled many to have unexpected months of a more normal life, researchers say.

source https://medicalxpress.com/news/2023-04-treatment-regimen-tolerated-beneficial-children.html